Wolf Popper LLP Announces Investigation on Behalf of Purchasers of CareDx, Inc. (CDNA) Common Stock
NEW YORK, October 29, 2021
Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of CareDx, Inc. (NASDAQ: CDNA) common stock.
CareDx develops and commercializes diagnostic solutions for transplant patients. After the market closed on October 28, 2021, CareDx announced strong third quarter 2021 results and increased its 2021 fiscal year revenue guidance. However, CareDx’s third quarter 2021 Form 10-Q disclosed that CareDx had received a civil investigative demand from the U.S. Department of Justice, and a subpoena from the Securities and Exchange Commission, both regarding business practices related to the company’s kidney testing and phlebotomy services. CareDx also said it received an information request from a state regulatory agency. On this news, CDNA’s intraday stock price is down $19.66 per share to $50.68, or a drop of 28.0%.
For more information, CareDx investors with trading losses of over $50,000 should contact Joshua Ruthizer at (212) 451-9668 or at firstname.lastname@example.org.
Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper’s reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm’s website at www.wolfpopper.com.
Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.
Wolf Popper LLP
845 Third Avenue
New York, NY 10022
Tel.: (212) 451-9668